ACM
Asymmetry Capital Management Portfolio holdings
AUM
$188M
This Quarter Return
+33.69%
1 Year Return
+45.88%
3 Year Return
+300.28%
5 Year Return
+633.15%
10 Year Return
–
AUM
$66.1M
AUM Growth
+$66.1M
(+47%)
Cap. Flow
+$18.6M
Cap. Flow
% of AUM
28.12%
Top 10 Holdings %
Top 10 Hldgs %
79%
Holding
27
New
5
Increased
9
Reduced
3
Closed
10
Top Buys
| 1 |
PTC Therapeutics
PTCT
|
$7.68M |
| 2 |
ACOR
Acorda Therapeutics, Inc.
ACOR
|
$6.23M |
| 3 |
XNPT
XENOPORT, INC.
XNPT
|
$5.09M |
| 4 |
UnitedHealth
UNH
|
$4.2M |
| 5 |
Quest Diagnostics
DGX
|
$2.34M |
Top Sells
| 1 |
DaVita
DVA
|
$4.07M |
| 2 |
Stryker
SYK
|
$2.61M |
| 3 |
MiMedx Group
MDXG
|
$2.22M |
| 4 |
ENDP
Endo International plc
ENDP
|
$1.84M |
| 5 |
Bristol-Myers Squibb
BMY
|
$1.77M |
Sector Composition
| 1 | Healthcare | 80.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
PTC Therapeutics
PTCT
$3.92B
| $7.68M | 11.62% | +237,100 | New | +$7.68M |
|
|
XNPT
2
DELISTED
XENOPORT, INC.
XNPT
| $7.11M | 10.76% | 1,295,778 +927,383 | +252% | +$5.09M |
|
|
3
Quest Diagnostics
DGX
$20.3B
| $6.65M | 10.05% | 93,445 +32,925 | +54% | +$2.34M |
|
|
ACOR
4
DELISTED
Acorda Therapeutics, Inc.
ACOR
| $6.23M | 9.41% | +145,509 | New | +$6.23M |
|
5
Centene
CNC
$14.3B
| $5.67M | 8.57% | 86,139 +35,355 | +70% | +$2.33M |
|
6
Teva Pharmaceuticals
TEVA
$21.1B
| $4.94M | 7.47% | 75,286 +27,201 | +57% | +$1.79M |
|
|
7
UnitedHealth
UNH
$281B
| $4.2M | 6.35% | +35,686 | New | +$4.2M |
|
8
Edwards Lifesciences
EW
$47.8B
| $3.73M | 5.64% | 47,230 +19,656 | +71% | +$1.55M |
|
|
NVRO
9
DELISTED
NEVRO CORP.
NVRO
| $3.71M | 5.61% | 54,927 -6,733 | -11% | -$455K |
|
10
Alkermes
ALKS
$4.78B
| $2.33M | 3.52% | +29,350 | New | +$2.33M |
|
11
Neurocrine Biosciences
NBIX
$13.8B
| $2.31M | 3.5% | 40,888 -8,612 | -17% | -$487K |
|
|
IPXL
12
DELISTED
Impax Laboratories, Inc.
IPXL
| $2.2M | 3.33% | 51,430 +13,151 | +34% | +$562K |
|
|
AERI
13
DELISTED
Aerie Pharmaceuticals, Inc.
AERI
| $2.09M | 3.16% | 85,895 +61 | +0.1% | +$1.49K |
|
14
Pacific Biosciences
PACB
$393M
| $1.91M | 2.89% | +145,306 | New | +$1.91M |
|
15
Amicus Therapeutics
FOLD
$2.34B
| $1.89M | 2.86% | 195,206 -37,751 | -16% | -$366K |
|
|
ANAC
16
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
| $1.76M | 2.66% | 15,591 +6,242 | +67% | +$705K |
|
|
SGYP
17
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $1.72M | 2.6% | 303,157 +100,002 | +49% | +$567K |
|
|
18
Bristol-Myers Squibb
BMY
$96B
| – | – | -29,900 | Closed | -$1.77M |
|
|
19
DaVita
DVA
$9.85B
| – | – | -56,290 | Closed | -$4.07M |
|
|
20
MiMedx Group
MDXG
$1.05B
| – | – | -229,839 | Closed | -$2.22M |
|
21
Penumbra
PEN
$10.6B
| – | – | -9,980 | Closed | -$400K |
|
|
22
Stryker
SYK
$150B
| – | – | -27,781 | Closed | -$2.61M |
|
23
Vanda Pharmaceuticals
VNDA
$279M
| – | – | -118,707 | Closed | -$1.34M |
|
|
CLVS
24
DELISTED
Clovis Oncology, Inc.
CLVS
| – | – | -16,458 | Closed | -$1.51M |
|
|
ENDP
25
DELISTED
Endo International plc
ENDP
| – | – | -26,600 | Closed | -$1.84M |
|